BOEHRINGER-INGELHEIM
9.7.2020 16:02:10 CEST | Business Wire | Press release
Results of a global survey of 1,375 adults aged at least 45 years old and living with Chronic Obstructive Pulmonary Disease (COPD) in 11 countries have been published in COPD: Journal of Chronic Obstructive Pulmonary Disease.1 Findings indicate that COPD has a substantial physical and psychosocial impact on patients, particularly those aged 45–54 years old. Compared with older patients (≥65 years old), this group more frequently reported that their COPD has a higher impact on their wellbeing and daily activities, and reported making more frequent adjustments to their activity due to their symptoms.1 Survey results indicate that there are significant quality of life and educational unmet needs, particularly amongst younger people living with COPD.
“This is one of the few surveys that looks at the impact of COPD in different age groups,” said Professor Dr Dekhuijzen, Pulmonologist, Radboud University Medical Center, Nijmegen, The Netherlands. “As healthcare professionals, we have to realise that the same disease has a different impact in younger and older patients, and that the perceived impact has to be addressed to tailor and optimise treatment to suit each patient.”
When looking specifically at the outcomes reported by younger patients (45–54 years old) versus older patients (≥65 years old):
- Younger patients more frequently reported that their COPD ‘extremely’ or ‘very much’ impacts their ability to carry out tasks outside the home (37% vs 22%) and travel long distances (38% vs 18%),1 and they were more than twice as likely to need to plan their day around periods of breathlessness and/or coughing (41% vs 19%)1
- A significantly higher proportion of patients aged 45–54 years old reported “poor” or “very poor” wellbeing (35% vs 28%; P<0.05), and reported feeling “stressed” and “overwhelmed” 1.7 and 2.2 times more frequently (P<0.05), respectively1
- Reliance on physicians was more significant amongst younger patients, who were more than three times more likely to want information to aid them to better manage using their inhaler device (18% vs 58% did not want this type of information)1
“One possible explanation as to why the perceived burden differs strongly is that younger patients are usually more active in terms of their work and social life, and so have differing expectations about what life with COPD will be,” said Nicole Hass, Representative from the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA). “Although more research is needed to better understand why these age differences exist, these findings show we need to make patients more aware of how they can positively impact their disease progression through things like speaking to clinicians about optimal treatment aimed at keeping them active in their daily lives.”
Findings reinforce the need for HCPs and COPD patients, particularly younger ones, to work towards optimal treatment management and therapy aimed at improving symptoms and lessening the impact of the disease on patients’ quality of life. According to Dr. Paola Casarosa, Head of Global Therapeutic Areas at Boehringer Ingelheim, “Overall, the results of this survey align with our ongoing efforts as an organisation, highlighting the importance of optimising treatment and helping patients to maintain active lives.”
Intended audiences:
Global and local, in-country medical media.
This press release is issued from our Corporate Headquarters in Ingelheim, Germany, and is intended to provide information about the results of our global COPD patient survey.
For references and notes to editors, please visit: http://www.boehringer-ingelheim.com/press-release/perceived-burden-copd-higher-younger-patients
Boehringer Ingelheim
View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005650/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 10:00:00 CEST | Press release
Barilla continues to advance its commitment to tastier products with less sugar and salt;An investment of 30 million euros in 2025 to quadruple photovoltaic capacity across plants, as part of a €168 million five-year plan focused on energy efficiency, renewable energy and sustainable water management.Barilla continues to expand regenerative agriculture practices across its global value chain, with over 816,000 tons of raw materials sourced through the Barilla Sustainable Farming program.4,000 tons of products donated worldwide and €2 million allocated to social causes in 2025, supporting communities across Barilla’s global footprint through food donations and social initiatives. A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal oppor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
